Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks

NCT02297945 is registered in ClinicalTrials.gov with HRA Pharma as lead sponsor.

NCT NCT02297945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02297945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks
Lead sponsor
HRA Pharma
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2015
Completion date
April 29, 2020
Enrollment
50 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

cushing's syndrome